A new option for remission induction in acute myeloid leukaemia

Affiliations

¹ Department of Medicine, Hematology, Oncology and Rheumatology, Heidelberg University, 69120 Heidelberg, Germany. Electronic address: carsten.mueller-tidow@med.uni-heidelberg.de.
² Trial Center, National Center for Tumor Diseases, Heidelberg, Germany.

Comment

Carsten Müller-Tidow et al. Lancet Oncol. 2018 Feb.

. 2018 Feb;19(2):156-157.

doi: 10.1016/S1470-2045(18)30012-3. Epub 2018 Jan 12.

¹ Department of Medicine, Hematology, Oncology and Rheumatology, Heidelberg University, 69120 Heidelberg, Germany. Electronic address: carsten.mueller-tidow@med.uni-heidelberg.de.
² Trial Center, National Center for Tumor Diseases, Heidelberg, Germany.

No abstract available

Comment on

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA. DiNardo CD, et al. Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12. Lancet Oncol. 2018. PMID: 29339097 Clinical Trial.